2012 annual report · in bringing innovative diagnostic and research tools to life science...
Post on 29-Sep-2020
2 Views
Preview:
TRANSCRIPT
2012 Annual Report
Helping all people live healthy lives
BD is a leading global medical technology company that develops,
manufactures and sells medical devices, instrument systems and reagents.
The Company is dedicated to improving people’s health throughout the
world. BD is focused on improving drug delivery, enhancing the quality
and speed of diagnosing infectious diseases and cancers, and advancing
research, discovery and production of new drugs and vaccines. BD’s
capabilities are instrumental in combating many of the world’s most
pressing diseases. Founded in 1897 and headquartered in Franklin Lakes,
New Jersey, BD employs nearly 30,000 associates in more than 50 countries
throughout the world. The Company serves healthcare institutions, life
science researchers, clinical laboratories, the pharmaceutical industry and
the general public. For more information, please visit www.bd.com.
Financial Highlights
Thousands of dollars, except per share amounts 2012 2011 Change
Operating results
Revenues $7,708,382 $7,584,037 1.6%
Income from continuing operations $1,109,528 $1,200,883 (7.6%)
Diluted earnings per share, from continuing operations $5.30 $5.31 (0.2%)
Dividends per common share $1.80 $1.64 9.8%
(1) Other is comprised of Latin America, Canada and Japan.
U.S. $3.288
Europe $2.379
Asia Pacific $.883
Other(1) $1.159
BD Medical
BD Diagnostics
BD Biosciences
$7.708
At a Glance
Revenue (billions of dollars)*
Revenue by Region (billions of dollars)
$4.091 Revenue
(billions of dollars)*
Medical Surgical Systems $2.105
Pharmaceutical Systems $1.074
Diabetes Care $.911
Customers Served
• Hospitalsandclinics
• Physicians’officepractices
• Consumersandretailpharmacies
• Governmentalandnonprofitpublichealthagencies
• Pharmaceuticalcompanies
• Healthcareworkers
Products
• Needlesandsyringes
• Intravenouscatheters
• Safety-engineeredandauto-disabledevices
• Prefillabledrugdeliverysystems
• PrefilledIVflushsyringes
• Insulinsyringesandpenneedles
• Regionalanesthesianeedlesandtrays
• Self-injectionsystems
• Sharpsdisposalcontainers
• Closed-systemdrugtransferdevices
BDMedicalisamongtheworld’sleadingsuppliersofmedicaldevicesandaleadinginnovatorininjection-andinfusion-baseddrugdeliverysince1906,whentheCompanybuiltthefirst-everfacilityintheU.S.tomanufactureneedlesandsyringes.TheBDMedicalsegmentisfocusedonprovidinginnovativesolutionstoreducethespreadofinfection,enhancediabetestreatmentandadvancedrugdelivery.
BD Medical
*Amounts may not add due to rounding.
$1.080 Revenue
(billions of dollars)
$2.538 Revenue
(billions of dollars)
Preanalytical Systems $1.301
Diagnostic Systems $1.237
Customers Served
• Hospitals,laboratoriesandclinics
• Referencelaboratories
• Bloodbanks
• Healthcareworkers
• Publichealthagencies
• Physicians’officepractices
• Industrialandfoodmicrobiologylaboratories
Customers Served
• Researchandclinicallaboratories
• Academicandgovernmentinstitutions
• Pharmaceuticalandbiotechnologycompanies
• Hospitalsandreferencelaboratories
• Bloodbanks
Products
• Integratedsystemsforspecimencollection
• Safety-engineeredbloodcollectionproductsandsystems
• Automatedbloodculturingsystems
• Moleculartestingsystemsforinfectiousdiseasesandwomen’shealth
• Microorganismidentificationanddrugsusceptibilitysystems
• Liquid-basedcytologysystemsforcervicalcancerscreening
• Rapiddiagnosticassays
• Platedmedia
• Microbiologylaboratoryautomation
BD MedicalBDDiagnosticsisaleadingproviderofproductsforthesafecollectionandtransportofdiagnosticsspecimens,aswellasinstrumentsandreagentsystemstoaccuratelydetectabroadrangeofinfectiousdiseases,healthcare-associatedinfections(HAIs)andcancers.TheBDDiagnosticssegmentfocusesonimprovinghealthoutcomesforpatientsbyprovidinglaboratorieswithsolutionsthatimprovequality,enhancelaboratorysystemproductivityandinformmedicaldecisions.
BD DiagnosticsBDBiosciencesisaworldleaderinbringinginnovativediagnosticandresearchtoolstolifescienceresearchers,clinicalresearchers,laboratoryprofessionalsandclinicianswhoareinvolvedinbasicresearch,drugdiscoveryanddevelopment,biopharmaceuticalproductionanddiseasemanagement.TheBDBiosciencessegmentisfocusedoncontinuallyadvancingthescienceandapplicationsassociatedwithcellularanalysis.
BD Biosciences
Products
• Fluorescence-activatedcellsortersandanalyzers
• Monoclonalantibodiesandkitsforcellanalysis
• Reagentsystemsforlifescienceresearch
• Cellimagingsystems
• Cellculturemediaandsupplementsforbiopharmaceuticalmanufacturing
“ Helping all people live healthy livesisaboutsharedvalue:creatingvalueforourshareholdersbystrengtheningthehealthofcommunitiesandaddressingthehealthcarechallengesofsocietiesthroughouttheworld.”
BD Biosciences
Vincent A. Forlenza Chairman, Chief Executive Officer and President
Dear Fellow Shareholders:
It’s a pleasure to write my first letter to you as CEO. First, I want to thank the BD associates around the world for their efforts which were the foundation of a successful year. Their passion for our purpose of “Helping all people live healthy lives” was unabated. While the global business environment remained volatile and challenging in 2012, it did not prevent us from achieving our financial goals while also advancing our strategy, innovation, operating efficiency and talent management programs, which I believe provide a strong platform for future success. We also made some important strategic choices during fiscal year 2012, including the decision to sell the majority of our BD Biosciences – Discovery Labware unit.
Infiscalyear2012,BDreportedrevenuesof$7.708billionanddilutedearningspersharefromcontinuingoperationsof$5.30,bothofwhichmetourexpectationsfortheyear.BDalsoreturned$1.9billiontoourshareholdersthroughacombinationofsharebuybacksanddividends,asweincreasedourdividendforthe40thconsecutivefiscalyear.Ourcashflowfromoperationstotaled$1.7billion,underlyingourstrongfinancialposition.
OurperformancethisyearwasdrivenbystrongperformancesinourBDMedicalandBDDiagnosticssegments.OurBDBiosciencesbusinesscontinuestobeimpactedintheU.S.byanuncertainresearchspendingenvironment.
Ourpipelinecontinuestomatureaswelaunched10newproductsin2012.Internationalsafetyproductsalesgrew10.5%versustheprioryearto$834million.Acquisitionsaddedabout100basispointstoourgrowthasweexperiencedstrongcustomeracceptanceofourBD PhaSeal,BD AccuriandBD Kiestraproducts.
Emergingmarketgrowthwasalsoapositivecontributor,reaching23%ofcompanysales,fueledbyoursecondyearofincreasedinvestment.SalesinChinagrewapproximately24.8%in2012.WealsoseepromisingopportunitiesinIndia,Vietnam,IndonesiaandLatinAmerica.
2012 Annual Report 1
Our Strategy
Ourstrategyistomakehealthcaremoreeffective,efficientandsaferthroughinnovationinareasthatleveragetheCompany’sclinicalknowledgeandexpertise.Wefocusprimarilyonimprovingparenteraldrugdelivery,includingthemanagementofdiabetes;improvingdiagnostictesting,primarilyforinfectiousdiseaseandcancer;andimprovingtechnologiesthatenableresearcherstounderstandthelivingcellsandtheirfunctions.Weseethisasaglobalmission,collaboratingwithgovernments,non-governmentalorganizationsandotherstakeholderstocreateanddeliversolutionstopressinghealthcarechallenges.Wehelptofundtheseeffortsthrougharelentlessfocusonoperatingeffectiveness.
Webelievetheprinciplesofsharedvaluearefundamentaltoourstrategy.Weprovideessentialvaluetosocietybyhelpingaddressunmethealthneeds,andthisinturnstrengthenstheCompany’sbusinessesandcreatesnewvalueforourshareholders.Theseprinciplesareafoundationfortheworkwedoaroundtheglobe,inbothindustrializedandemergingmarketsettings,includingresource-limitedcountries.Weremaincommittedtosharingthebenefitsofthisstrategythroughareturnofcapitaltoshareholdersviadividendsandsharebuybacks.
Investing for the Future
Inlinewithourbeliefthattechnologysolutionscanreducehealthcarecostsandimprovecare,weinvested$472millioninR&Dandallocated$487millionofcapitaltonewplantsandequipment.Wewerepleasedthatmultiplenewproductandtechnologyprogramsprogressedasplanned.TheBD MAXSystem,alongwithtwoassaysforbacterialinfections,wasapprovedintheU.S.BDBioscienceslaunchedtheBD FACSJazzCellSortingSystem,whichforthefirsttimeoffersanextremely
powerfultoolfortheidentificationandisolationofsingleormultiplecells,evenfromcomplexorextremelyrarecellpopulations,rightfromthebenchtop.TheBD NanoPenNeedle,theworld’ssmallestpenneedle,continuedtofindacceptanceamongpeoplewithdiabeteslookingforabetterinjectionexperience.WealsomadeprogressonourinfusioncollaborationwiththeJuvenileDiabetesResearchFoundation(JDRF)andinitiatedasecondcollaborationtodevelopacontinuousglucosesensor.
Wecomplementedourinternalinnovationprogramswithstrategicacquisitions,includingKIESTRALabAutomation.ThecombinationofBD’sbroadportfolioofmicrobiologyplatforms,reagentsandsupplieswithKIESTRA’sautomatedinstrumentationtechnologieswillprovideuswiththetechnologicalfoundationtoofferinnovativetotallabautomationsolutionstohospitalsandlaboratoriesworldwide.WealsoacquiredSirigenGroupLimited,amakerofflow
cytometrydyes,whichwebelievewillenablemorecomplexexperimentsandfasterresultsforourcustomers.
Webelievethatthehealthcareenvironmenthasfundamentallychangedinthedevelopedworld.Evenwhentheglobaleconomyimproves,weexpectconsumersandgovernmentstocontinuetobemorediscerningbuyersofhealthcare.Howarewemeetingthischallenge?First,wehaveredirectedmoreofourR&Dspendawayfromlineextensionsandtowardprogramsthatwillhaveagreaterimpactonimproving
patientoutcomesandtheefficiencyofhealthcare.Second,wearealsoextendingourreachintolower-pricedemergingmarketsegmentswithmoreprice-competitiveproducts,suchasthenewhigh-quality,low-costBD EmeraldSyringeline.Third,wearedrivinghardtolowerourcosts.IamproudtosaythatourReLoCocostreductionprogramsachievedtheirmilestonesduringfiscalyear2012.Weexpecttorealizeincrementalnetcostsavingsof$40to$50millioninfiscalyear2013.
Dividends Paid vs. Shares Repurchased($ millions)
SHARES REPURCHASED
DIVIDENDS PAID
$550
$317
$750
$1,500 $1,500
$346 $361 $368
2012201120102009
“ We have redirected more of our R&D spend…toward programs that will have a greater impact on improving patient outcomes and the efficiency of healthcare.”
2 BD
BD Medical
Manypeoplewithdiabetesarehesitantorunwillingtogivethemselvesinsulininjectionsforreasonsincludingneedleanxiety.TheBD Ultra-Fine NanoPenNeedlewithPentaPointComfort,BD’slatestadvancementininjectioncomfort,isapatented5-bevelneedletipdesignthatcreatesaflatter,thinnersurfacetohelppenetratetheskinwithsignificantlygreaterease.Thiswillhelpenablepatientstoadheremoreeasilytotherapyregimensrecommendedtoimprovetheiroutcomes.
BD Diagnostics
Microbiologylabsarefacingunprecedentedchallengeswhiletheneedforfasterdeliveryofmoreaccurateresultsisincreasingtoensureoptimalpatientcare.ThroughouracquisitionofKIESTRA,theleaderinTotalLabAutomation,wehaveexpandedourmicrobiologyportfoliotoincludenewautomatedinstrumentationtechnologiesthatwillenableustoofferinnovativetotallabautomationsolutionstolaboratoriesworldwide.
BD Biosciences
Today,scientistsfamiliarwithflowcytometrychoosedyesbasedonthenumberofsurfacereceptorsonthecellstheyarestudying,aswellastheirbrightness.WeacquiredSirigenanditspolymerdyes,whichhavethepotentialtoaddcolorchoicesandsimplifyflowforbothexpertandnoviceusers.Thesenewtechnologiesenableadeeperlevelofbiologicalstudywithmoreandbrightercolorchoicesforcomplexmulticolorflowexperiments.
BD Innovations
Also,in2012wesuccessfullyimplementedthefirstwaveofEVEREST,ournext-generationenterpriseresourceplanningsystem,atanumberofU.S.sites.Workhasbegunattheremainingsites,andweexpecttocompletethenextsetofimplementationsinthefallof2013,withtheprogramfinishinginmid-2014.EVEREST,alongwithournetworkofsharedservicecenters,willprovideuswiththesystemstomeetthecostandoperatingchallengesofanincreasinglyglobalcompany.
Environmental Performance
Iampleasedtoreportcontinuedprogressthisyearinsustainableoperationsandproductstewardship,whicharethefocusofBD’senvironmentalsustainabilitystrategy.Oursitesaroundtheworldhavereducedenergy,waterandwaste,contributingtoprogressagainstour2015SustainabilityTargets.
Wecurrentlyuse35%renewableenergyinouroperations,exceedingour2015renewableenergygoal,andwehavereducedenergyconsumptionby13%indexedtocostofgoodssoldagainstourgoalof30%.Whencombinedwithourrenewableenergyuse,thishasresultedina21.6%(absolute)reductioningreenhousegasemissions.Inaddition,wereducedhazardouswasteby44%indexedtocostofgoodssold,farexceedingouroriginalgoalofa10%reduction.
BDisalsoproudtohavebecomeaWindMadeTMPioneerCompanythisyear.WindMadeisthefirstconsumer
labelingprogramtocertifycompaniesthatsourceatleast25%oftheirpowerfromwindenergy.AsaPioneerCompany,BDisamonganelitegroupoforganizationssupportingthelabel,whichwillhelpusmoreeffectivelycommunicateourrenewableenergyusetocustomersandcompanystakeholders.Justrecently,BDreceivedtheWindMadeTMlabelforourglobaloperations,certifyingthat35%ofourtotalelectricityuseisfromwindpower.WeinviteyoutoreadmoreaboutourcommitmenttosustainabilityinBD’sSustainabilityReportatwww.bd.com/sustainability.
“ We received the WindMadeTM label for our global operations, certifying that 35% of our total electricity use is from wind power.”
2012 Annual Report 3
Global Health
Often,thewaytomakeasignificantdifferenceinaddressingglobalhealthcareneedsisthroughcollaborationswithorganizationsthathavecomplementaryskills,expertiseandresources.Thisyear,wecollaboratedwithHearttoHeartInternational,ahumanitarianmedicalaidnonprofitorganization,forasecondjointvolunteerinitiativetostrengthenhealthcareinHaiti.WealsocollaboratedwithDirectReliefInternationaltovaccinatethreemillionHaitianchildrenformeasles,rubellaandpolioinacampaignestablishedbyHaiti’sMinistryofHealth.BDprovidedmorethan1.7millionauto-disableimmunizationsyringesand150,000sharpsdisposalcontainers.
InJuly,weannouncedanewcollaboration,Labs for Life,withtheU.S.President’sEmergencyPlanforAIDSRelief(PEPFAR),throughtheOfficeoftheU.S.GlobalAIDSCoordinatorandtheU.S.CentersforDiseaseControlandPrevention(CDC).ThegoalistohelpstrengthenhealthcareandlaboratorysystemsincountrieshighlyimpactedbytheHIV/AIDSepidemic.Valuedat$20million,thiscollaborationbuildsonapriorfive-yearpublic-privatepartnershipbetweenBDandPEPFARthatfocusedonimprovingoveralllaboratorysystemsandservicesintargetedsub-SaharanAfricancountries.ThisnewcollaborationwillfocusitsinvestmentsinUganda,Kenya,Ethiopia,
MozambiqueandIndia.OurongoingworkwithPEPFARhasdemonstratedhowtheprivatesector,inpartnershipwithgovernments,caneffectivelyapplyitstechnologiesandexpertisetohaveapositiveimpactonhealthcareintheregionsmostheavilyburdenedbyinfectiousdisease.
IntheU.S.,wecollaboratedwiththeAssociationforProfessionalsinInfectionControlandEpidemiology(APIC),throughtheHeroesofInfectionPreventionAwardprogramandtheHeroesImplementationResearchScholarAward.Webelievethatsupportingresearchandlearningwillhelpensurethatthelargerinfectionpreventioncommunityhastheabilitytoreplicatebestpracticesinabroadrangeofhealthcaresettings.
Executive Appointments
Wewereverypleasedtopromotetwonewregionalleaderstoourexecutiveteamthisyear:AlexConroy,PresidentforEurope,EMA(EasternEurope,MiddleEastandAfrica)andtheAmericas,andJamesLim,PresidentforGreaterAsia.AlexandJamesbringin-depthknowledgeoftheseregions,andtheirinsightswillenableustoacceleratetheglobalizationofBD.Additionally,NabilShabshab,whojoinedusinlate2011asourSeniorVicePresidentandChiefMarketingOfficer,ismakingexcellentprogressdrivingcustomerinsightsmuchdeeperintoourplanning,developmentprogramsandgo-to-marketefforts.
Key Board Developments
WeareextremelypleasedtowelcomeRebeccaRimel,PresidentandChiefExecutiveOfficerofThePewCharitableTrusts,toourBoardofDirectors.ShebringstoBDauniqueblendofbroadpublicpolicyexpertise,philanthropicleadershipandastronghealthcarebackground.ShehasalreadybeenanassettotheBoard.
IwouldliketothanktheBoard,andinparticularmypredecessor,EdLudwig,whoretiredthisyear,fortheirguidanceandsupportduringthisexecutivetransition.Whileachangeinleadershipissignificantinanycompany,Ed’sretirementmarkedonlythesixthtimeinBD’s115-yearhistorythatwehavetransitionedCEOs.I’mverygratefultoEd,asamentorandafriend,forhishelpinpreparingmeandtheCompanyforthistransition.
In Closing
AtBD,weunderstandthatourgreatestassetisthetrustweearn,byfulfillingourcommitmentsandbeingtruetoourpurposeofHelping all people live healthy livesanddoingsoinaccordancewithourCoreValues.Weknowwedonotoperatealoneandweappreciatethesupportofourpartners,customersandshareholders.Healthcaresystemsandpatientsallovertheworldarefacingmajordifficulties.Webelievewecanhelp.Ibelievewehavetherightstrategyandwearebuildingtherightcapabilitiestodoourparttoimprovehealthcareglobally.
Thankyoufortheopportunitytoleadthisgreatcompany.
Vincent A. Forlenza Chairman,ChiefExecutiveOfficerandPresident
4 BD
BD Around the World
North America » New East Coast Distribution Center opens in Four Oaks, North Carolina.
» The BD Veritor System for rapid detection of Flu A+B delivers very good analytical sensitivity and specificity.
» In the U.S., BD offers BD Ultra-Fine Nano 4mm Pen Needles with PentaPoint Comfort.
» In the U.S., BD is donating insulin syringes and pen needles through Direct Relief to community health centers and free clinic partners.
South America » The new BD Emerald Syringe product portfolio combines high-quality performance with a design that uses up to 30% less material than other syringes.
» In collaboration with the National Cancer Coalition, BD has committed to give 75,000 underserved Peruvian women access to BD SurePath liquid-based cytology tests over the next three years.
Europe » The new safety-engineered BD Vacutainer Eclipse Signal Blood Collection Needle is now available.
» The BD MAX MRSA Assay has launched in Europe.
» New European Shared Service Center opened in Poland.
Africa » BD, the Kenya Ministry of Medical Services and PEPFAR launched the Center for Excellence in Phlebotomy and Specimen Collection at the Kenya Medical Training College.
» Tanzania Initiative for Blood-Drawing Applications (TIBA), a multi-year BD collaboration with PEPFAR, aims to train healthcare workers to improve blood draw practices; expands needlestick injury prevention, surveillance and post-exposure management; and provides a framework to improve policies, guidelines and standard operating procedures.
Asia Pacific » New R&D Center opened in India as part of BD’s efforts to accelerate innovation to develop new products.
» Public-private collaboration initiated in China to strengthen prevention and control of healthcare-associated infections.
2012 Annual Report 5
FORTUNE is a registered trademark of Time Inc. and is used under license. From FORTUNE Magazine, March 19, 2012 © 2012 Time Inc. FORTUNE and Time Inc. are not affiliated with, and do not endorse products or services of, Licensee.
From Forbes, September 24, 2012 © 2012 Forbes. All rights reserved. Used by permission and protected by the Copyright Laws of the United States. The printing, copying, redistribution, or retransmission of this Content without express written permission is prohibited.
12 13
MOSTINNOVATIVECOMPANIES
2012/13
2012
Corporate Sustainability
» World’sMostEthicalCompanies—EthisphereCouncil,
sinceinauguralyearin2007
» World’sMostAdmiredCompanies—FORTUNE
» DowJonesSustainabilityWorldIndex,since2006
» DowJonesSustainabilityNorthAmericanIndex,since2005
» FTSE4GoodIndex,since2003
Innovation
» World’sMostInnovativeCompanies—Forbes
» NewJerseyTechnologyCouncil—PublicCompany
oftheYear
» NewJerseyInventorsHallofFame—CorporateAward
Employer of Choice
» BestEmployersforHealthyLifestyles—NationalBusinessGrouponHealth(U.S.)
» BestEmployers™SouthAfrica—CorporateResearch
FoundationInstitute
» BestPlacestoWorkinNewJersey—NJBIZ,since2005
» CEOCancerGoldStandard™Accreditation
» EmployerofChoiceforWomeninAustralia—EqualOpportunityforWomenintheWorkplace
Environment, Health and Safety
» U.S.EPAGreenPowerPartnershipMember—2012LeadershipClub
» GreenRankings—Newsweek
» WindmadeTM—PioneerCompany
» ChampionforChangeEnvironmentalExcellenceAward—PracticeGreenhealth
» U.S.EPASmartWay®TransportPartner—Member
2012 Awards, Recognitions and Affiliations
6 BD
Thegraphbelowpresentsacomparisonofcumulativetotalreturntoshareholdersforthefive-yearperiodendedSeptember30,2012forBD,theS&P500IndexandtheS&P500HealthCareEquipmentIndex.
Cumulativetotalreturntoshareholdersismeasuredbydividingtotaldividends(assumingdividendreinvestment)pluspersharepricechangefortheperiodbythesharepriceatthebeginningofthemeasurementperiod.BD’scumulativeshareholderreturnisbasedonaninvestmentof$100onSeptember30,2007andiscomparedtothecumulativetotalreturnoftheS&P500IndexandtheS&P500HealthCareEquipmentIndexoverthesameperiodwithalikeamountinvested.
Sep 07
June
08
June
09
June
10
Dec 07
Mar
08
Sep 08
Dec 08
Mar
09
Sep 09
Dec 09
Mar
10
Sep 10
Dec 10
Mar
11
June
11
Sep 11
Dec 11
Mar
12
June
12
Sep 12
Becton, Dickinson and Company S&P 500 Index S&P 500 Index Health Care Equipment Index
Dollars
0
50
100
150
*Source: Standard & Poor’s
COMPARISON OF 5-YEAR CUMULATIVE TOTAL RETURNAMONG BECTON, DICKINSON AND COMPANY, THE S&P 500 INDEX,
AND THE S&P 500 HEALTH CARE EQUIPMENT INDEX*
Corporate InformationAnnual MeetingTuesday,January29,2013–1:00p.m.HiltonShortHills41JohnF.KennedyParkwayShortHills,NJ07078
This annual report is not a solicitation of proxies.
Transfer Agent and RegistrarComputershareTrustCompany,N.A.250RoyallStreetCanton,MA02021Phone:1-877-498-8861International:1-781-575-2726Internet:www.computershare.com
Direct Stock Purchase PlanTheDirectStockPurchasePlanestablishedthroughComputershareTrustCompany,N.A.,enhancestheservicesprovidedtoexistingshareholdersandfacilitatesinitialinvestmentsinBDshares.PlandocumentationandadditionalinformationmaybeobtainedbycallingComputershareTrustCompany,N.A.,at1-877-498-8861,orbyaccessingthe“Buystockdirect”featurelocatedwithintheInvestorCentreofComputershare’swebsiteatwww.computershare.com.
NYSE Symbol: BDX
Independent AuditorsErnst&YoungLLP5TimesSquareNewYork,NY10036-6530Phone:1-212-773-3000Internet:www.ey.com
Shareholder InformationAtNovember9,2012,BDhad8,676shareholdersofrecord.BD’sStatementofCorporateGovernancePrinciples,BD’sCodeofConduct,thechartersofBD’sCommitteesoftheBoardofDirectors,BD’sreportsandstatementsfiledwithorfurnishedtotheSecuritiesandExchangeCommissionandotherinformationarepostedonBD’swebsiteatwww.bd.com/investors.
Shareholders may receive, without charge, printed copies of these documents, including BD’s 2012 Annual Report on Form 10-K, including the financial statements and related schedules, by contacting:InvestorRelationsBD1BectonDriveFranklinLakes,NJ07417-1880Phone:1-800-284-6845Internet:www.bd.com
The trademarks indicated by italics are the property of Becton, Dickinson and Company, its subsidiaries or related companies. © 2012 BD
All other brands and logos represented herein are trademarks of their respective owners.
2012 Annual Report 7
Corporate OfficersVincent A. ForlenzaChairman,ChiefExecutiveOfficerandPresident
Pierre BoisierSeniorVicePresident,Quality
Donna M. BolesSeniorVicePresident,HumanResources
Gary M. CohenExecutiveVicePresident
Alexandre ConroyPresident,Europe,EMAandtheAmericas
Gary M. DeFazioVicePresidentandCorporateSecretary
John E. GallagherVicePresidentandTreasurer
David W. HighetVicePresidentandChiefIntellectualPropertyCounsel
William A. KozyExecutiveVicePresidentandChiefOperatingOfficer
James LimPresident,GreaterAsia
Richard J. NaplesSeniorVicePresident,RegulatoryAffairs
Wiliam E. RhodesSeniorVicePresident,CorporateStrategyandDevelopment
Patti E. RussellVicePresidentandChiefEthicsandComplianceOfficer
Antoinette F. SegretoVicePresident,Tax
Nabil ShabshabSeniorVicePresidentandChiefMarketingOfficer
Jeffrey S. ShermanSeniorVicePresidentandGeneralCounsel
Stephen Sichak, Jr.SeniorVicePresident,IntegratedSupplyChain
Suketu UpadhyayActingChiefFinancialOfficer,SeniorVicePresidentandController
Board of DirectorsBasil L. Anderson1,2,4
RetiredViceChairman—Staples,Inc.
Henry P. Becton, Jr.3,4,5
ViceChairmanandformerPresident—WGBHEducationalFoundation
Edward F. DeGraan2,3,4
RetiredViceChairman—GilletteProcter&GambleCompany
Vincent A. Forlenza4
Chairman,ChiefExecutiveOfficerandPresident
Claire M. Fraser, Ph.D.3,5
Director—InstituteofGenomeSciences,UniversityofMarylandSchoolofMedicine
Christopher Jones1,5
RetiredChiefExecutiveOfficer—JWTWorldwide
Marshall O. Larsen1,2
RetiredChairman,PresidentandChiefExecutiveOfficer—GoodrichCorporation
Adel A. F. Mahmoud, M.D., Ph.D.3,5
Professor,DepartmentofMolecularBiologyandtheWoodrowWilsonSchoolofPublicandInternationalAffairs—PrincetonUniversity
Gary A. Mecklenburg1,5
RetiredPresidentandChiefExecutiveOfficer—NorthwesternMemorialHealthCare
James F. Orr 1,2,4
RetiredChairmanandChiefExecutiveOfficer—ConvergysCorporation
Willard J. Overlock, Jr.2,3,4
RetiredPartner—Goldman,Sachs&Co.
Rebecca W. Rimel1,5
PresidentandChiefExecutiveOfficer—ThePewCharitableTrusts
Bertram L. Scott1,2
PresidentandChiefExecutiveOfficer—AffinityHealthPlan
Alfred Sommer, M.D., M.H.S.3,4,5
ProfessorofInternationalHealth,EpidemiologyandOphthalmology—JohnsHopkinsUniversityMedicalSchoolandBloombergSchoolofPublicHealth
Committees appointed by the Board of Directors
1– Audit Committee 2– Compensation and Benefits Committee 3– Corporate Governance and Nominating Committee 4– Executive Committee 5– Science, Innovation and Technology Committee
8 BD
Printing Information*To conserve resources and limit environmental impact, the content of this printed report has been printed on Mohawk Silk Loop, an FSC-certified paper that is made using renewable energy. Compared to a standard paper stock,this paper represents the following environmental savings:
84trees preserved for the future
243 lbswater-borne waste not created
35,815 galwastewater flow saved
3,963 lbssolid waste not generated
7,802 lbs netgreenhouse gases prevented
59,720,150 BTUsenergy not consumed
22,081 lbs ghgemissions not generated
9,053 windpower savings13,028 carbon offset savings
24 barrelsfuel oil unused
10 windpower savings24 carbon offset savings
equivalent to not driving
2 mi 1 windpower savings1 carbon offset savings
equivalent to planting
1,502 trees 618 windpower savings886 carbon offset savings
*Source: Mohawk Fine Papers Inc.
1 Becton DriveFranklin Lakes, NJ 07417www.bd.com
top related